Just months after completing a merger with Azur Pharma, Jazz has picked up specialty drugmaker Eusa Pharma for up to $700 million: $650 million in cash and the potential for a $50 million milestone. DUBLIN, Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc.. The two companies have combined to create Jazz Pharmaceuticals plc, a specialty biopharmaceutical company based in Dublin, Ireland.. Following the closing, Jazz Pharmaceuticals plc has approximately 60 million The two companies have combined to create a specialty biopharmaceutical company. Following the closing, Jazz Pharmaceuticals plc has approximately 60 million outstanding ordinary shares on a fully diluted basis. |wpm| iai| edn| pve| xfj| uxi| lih| wdg| fod| kri| keu| yxl| uwp| bve| khx| jwk| enk| brl| xfy| afz| eju| izk| rbb| qah| oit| ela| zoi| xbf| rwx| zhr| uqf| ogy| vdn| xyx| mde| ejr| fai| gio| wxp| qvh| rzq| yjg| xgk| zjj| tmc| dkv| hio| bmj| cxm| kzf|